arrow
T

Tetsunari Hase

Nagoya University
H指数:28
被引数:2,443

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab

阿特珠单抗治疗晚期NSCLC患者外周血T细胞谱及血浆蛋白质组学分析

2026-02-020
OAAI
Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab

培美曲塞联合铂类药物作为接受纳武利尤单抗联合伊匹木单抗治疗的患者中,恶性胸膜间皮瘤的二线治疗方案。

2025-08-120
PRE
Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events

重度免疫相关不良事件后再次使用免疫检查点抑制剂的 safety 和 efficacy

2025-06-013
OAAI
Development of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: a prospective study with immortal time bias correction
2024-11-070
OAAI
Synthetic retinoid-mediated preconditioning of cancer-associated fibroblasts and macrophages improves cancer response to immune checkpoint blockade
2024-06-074
OA
Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L)

前瞻性观察研究,以探索预测布格替尼对ALK基因重排非小细胞肺癌的疗效和安全性的基因和蛋白质: ABRAID研究的研究方案 (WJOG11919L)

2024-01-270
OAAI
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis
2023-05-123
OA
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

使用日本上市后所有病例监测数据对Pembrolizumab单药治疗NSCLC的真实数据分析

2022-11-013
OA
Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade
2022-08-0313
OA
Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline
2021-11-1520
OA
Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival
2021-11-0714
OAAI
SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas
2021-09-1521
OA